COL25A1 and METAP1D DNA methylation are promising liquid biopsy epigenetic biomarkers of colorectal cancer using digital PCR.

Fiche publication

Date publication

octobre 2024

Journal

Clinical epigenetics

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BORG Christophe , Pr GUITTAUT Michaël , Mr MONNIEN Franck , Dr HERVOUET Eric , Dr PEIXOTO Paul , Dr VIENOT Angélique , Pr FEUGEAS Jean-Paul , Dr SELMANI Zohair , Dr MOLIMARD Chloé

Tous les auteurs :
Overs A, Peixoto P, Hervouet E, Molimard C, Monnien F, Durand J, Guittaut M, Vienot A, Viot J, Herfs M, Borg C, Feugeas JP, Selmani Z

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/39425144

Résumé

Colorectal cancer is a public health issue and was the third leading cause of cancer-related death worldwide in 2022. Early diagnosis can improve prognosis, making screening a central part of colorectal cancer management. Blood-based screening, diagnosis and follow-up of colorectal cancer patients are possible with the study of cell-free circulating tumor DNA. This study aimed to identify novel DNA methylation biomarkers of colorectal cancer that can be used for the follow-up of patients with colorectal cancer.